RCS - Kromek Group PLC - Kromek detectors used in digital SPECT/CT scanner

KromekAnnouncement

17/10/2022 11:45

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221017:nRSQ1249Da&default-theme=true

RNS Number : 1249D  Kromek Group PLC  17 October 2022

 

17 October 2022

Kromek Group plc

("Kromek" or the "Group")

 

Kromek's digital detectors used in world's first digital SPECT/CT scanner for
higher energy imaging

Detectors provide Spectrum Dynamics Medical's digital SPECT/CT scanner with
higher sensitivity and throughput

 

Kromek Group plc (AIM: KMK), a leading developer of radiation and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments, is pleased to announce that one of its key customers, Spectrum
Dynamics Medical, has introduced the world's first digital SPECT/CT scanner
for higher energy imaging,  using Kromek's digital detectors.

 

Based on Spectrum Dynamics' digital SPECT/CT platform, VERITON-CT 400 Series'
detector technology provides the benefits of increased sensitivity and
throughput for Nuclear Medicine clinical applications using up to 400keV
high-energy isotopes.

 

CZT is transforming the detector technology used in medical imaging leading
to shorter scan times, lower radiation dose to the patient, and improved image
quality and quantitative accuracy.

 

Kromek's high-performance digital detectors, combined with Spectrum's
360-degree, wide-bore SPECT/CT scanner and its advanced image reconstruction
algorithms, increase the energy range up to 400 keV to support the throughput
demand of current and new emerging nuclear medicine clinical applications.

 

The 400 Series digital detector technology sets new standards with a 2-4 times
improvement in energy range, system sensitivity, and energy resolution. These
improvements will significantly shorten the scan times associated with current
analog or state-of-the-art digital technology.

 

Arnab Basu, CEO of Kromek Group, said: "We are delighted that our CZT
detectors have been integrated into Spectrum Dynamics' VERITON-CT 400 SPECT/CT
systems. This enables enhanced image quality and breakthrough clinical
capabilities in digital SPECT/CT. Spectrum Dynamics has long been at the
forefront of developing next-generation SPECT/CT scanners to deliver better
patient outcomes, and we are pleased to be part of this significant advance in
nuclear medical imaging technology."

 

Gilad Yoeli, CEO of Spectrum Dynamics, added: "Clinical users across the world
provide us with feedback on the Nuclear Medicine challenges they face.
Providing the technology to address such challenges is what drives us. The
increased sensitivity, improved energy resolution, and broader energy range of
Kromek's detector technology make it the right choice for the 400 Series and
the advanced imaging and quantitative accuracy clinical users ask for."

 

 

For further information, please contact:

 

 Kromek Group plc
 Arnab Basu, CEO                                                 +44 (0)1740 626 060

 Paul Farquhar, CFO

 Spectrum Dynamics Medical                                       +1 (941) 441-6224

 Nilda Rivera

 finnCap Ltd (Nominated Adviser and Broker)
 Geoff Nash/Seamus Fricker/George Dollemore - Corporate Finance  +44 (0)20 7220 0500

 Tim Redfern/Charlotte Sutcliffe - ECM

 Gracechurch Group (Financial PR)
 Harry Chathli, Claire Norbury                                   +44 (0)20 4582 3500

 

About Kromek Group plc

 

Kromek Group plc is a leading developer of radiation detection and
bio-detection technology solutions for the advanced imaging and CBRN detection
segments. Headquartered in County Durham, UK, Kromek has manufacturing
operations in the UK and US, delivering on the vision of enhancing the quality
of life through innovative detection technology solutions.

 

The advanced imaging segment comprises the medical (including CT and SPECT),
security and industrial markets. Kromek provides its OEM customers with
detector components, based on its core cadmium zinc telluride (CZT) platform,
to enable better detection of diseases such as cancer and Alzheimer's,
contamination in industrial manufacture and explosives in aviation settings.

 

In CBRN detection, the Group provides nuclear radiation detection solutions to
the global homeland defence and security market. Kromek's compact, handheld,
high-performance radiation detectors, based on advanced scintillation
technology, are primarily used to protect critical infrastructure and urban
environments from the threat of 'dirty bombs'.

 

The Group is also developing bio-security solutions in the CBRN detection
segment. These consist of fully automated and autonomous systems to detect a
wide range of airborne pathogens.

 

Kromek is listed on AIM, a market of the London Stock Exchange, under the
trading symbol 'KMK'.

 

Further information is available at www.kromek.com (http://www.kromek.com) .

 

 

About Spectrum Dynamics Medical

 

Spectrum Dynamics Medical Group Limited and its subsidiaries ("Spectrum
Dynamics") are engaged in developing, manufacturing, selling, and servicing
state-of-the-art nuclear medicine imaging systems. Spectrum Dynamics is
spearheading the transformation of SPECT imaging systems from analog to
digital detection technology, enabling hospitals and clinicians to provide
superior healthcare services with improved image quality, efficiency, and
access to advanced clinical applications. Spectrum Dynamics launched the
world's first digital cardiac dedicated SPECT system - the D-SPECT® CARDIO -
in 2007. Since then, the D-SPECT has become the system of choice for
functional cardiac imaging, with hundreds of systems sold worldwide. In 2018,
Spectrum Dynamics launched its multipurpose VERITON® and the VERITON-CT®
SPECT/CT, the first ring-based 360 CZT digital SPECT/CT scanner.

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABDLFFLBLZFBB